Particle.news
Download on the App Store
4 ARTICLES
·
1h ago

NHS Performs First Histotripsy Liver Cancer Treatment at Addenbrooke’s

Fast-track authorization under the MHRA’s Innovative Devices Access Pathway made early NHS use possible at Addenbrooke’s.

Roger Jackson, 80, was the first patient in Europe to benefit from the treatment and is now back at home
Image
Image

Overview

  • Roger Jackson, 80, underwent the incisionless ultrasound procedure earlier this month and was discharged the next day.
  • Addenbrooke’s Hospital is the first centre in Europe to offer histotripsy outside clinical trials and is currently the only UK provider as it establishes a referral pathway.
  • Histotripsy uses focused sound waves to create microscopic bubble clouds that mechanically destroy tumour tissue in about 30 minutes without surgery, radiation or chemotherapy.
  • The device received Unmet Clinical Need Authorisation in Great Britain, a conditional route overseen by the MHRA that allows controlled early access before full approval.
  • Developed by US-based HistoSonics and FDA-cleared for liver tumours in 2023, the technology has treated over 2,000 patients worldwide, with NHS use initially limited to selected primary and secondary liver cancer cases as further studies and NIHR-supported evaluations progress.